Clinical Trials
6 trialsNCT06514794 2026-05-12
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
Phase 2 Recruiting
NCT04703192 2025-12-09
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Daiichi Sankyo
Phase 2 Active not recruiting
NCT04102150 2025-02-10
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
Daiichi Sankyo
Phase 2 Completed
NCT02955589 2024-09-19
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
HUYABIO International, LLC.
Phase 2 Completed
NCT01626664 2024-04-25
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated